CHMP

#CHMP #EMA #Ipsen #Marketing approval authorisation #Phase III trial #Regulatory

CHMP rejects rare bone disease treatment in EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorisation for Ipsen’s investigational palovarotene as a treatment for fibrodysplasia ossificans progressiva (FOP).   The company says it will be requesting a re-examination of the CHMP opinion, based on scientific… Read More

#News #Regulatory

Woman having epileptic fit
#CHMP #epilepsy #Europe #Neuroscience #Rare disease

Treatment for severe form of epilepsy approved in Europe

UCB’s Fintepla (fenfluramine) oral solution has been recommended for marketing authorisation in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare, severe form of epilepsy.  The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion… Read More

#News #Regulatory

Gene therapy for haemophilia
#Cell and gene therapy #CHMP #CSL #Europe #Gene therapy #Haemophilia

First gene therapy for haemophilia B gets go ahead in Europe

The first gene therapy for haemophilia B could soon be available to patients in Europe following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).  The CHMP has recommended conditional marketing authorisation of CSL’s etranacogene dezaparvovec, a one-time gene therapy for the treatment of appropriate adults… Read More

#News #Regulatory #Trending News